Transfusion Journal/ transfusion.org
Aug 28, 2025, 18:54
Albert Farrugia: When Will FV Deficiency Get the Attention It Deserves?
Albert Farrugia, Clinical professor at The University of Western Australia, shared an insightful post on LinkedIn:
“The largest series, as far as I’m aware, on the use of FX concentrate in this extremely rare deficiency.
When are we going to see some effort for FV deficiency. I anticipate efficacy with many of the bypassing agents.
It’s disappointing not to see FV deficient patients included in the trials.
Read the full article:”
Article: Characterization and management of patients with hereditary factor X deficiency: A case series
Authors: Meera Chitlur, Lauren E. Amos, Mark T. Reding, Cynthia Sabo, Suchitra S. Acharya
Stay updated with Haemostasis Today.
-
Jul 21, 2026, 19:44Shinya Goto: JCS/JPCPHS 2025 Guideline Now Available in English
-
Jul 21, 2026, 19:43Abdul Mannan: Why Is HbS or HbD Approximately 40% in Heterozygotes Rather Than 50%?
-
Jul 21, 2026, 19:42Haemophilia Maintains a 2025 Impact Factor of 3.0 – WFH
-
Jul 21, 2026, 19:41Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
-
Jul 21, 2026, 19:40Filmon Tesfay: Our New Case Report on Cerebral Venous Thrombosis Is Now Published
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis